




SQi

DIAGNOSTICS

science quality innovation

Investor Information May 2019



FORWARD LOOKING STATEMENTS

This presentation may contain certain statements including, without limitation, the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in the process”, “benefits”, “leading to”, “possible”, “is subject to” and other similar expressions which may constitute “forward-looking statements” within the meaning of applicable securities laws.

Forward-looking statements reflect the Company's current expectations and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. Readers are cautioned not to place undue reliance on these forward-looking statements. These forward-looking statements involve risks and uncertainties including, but not limited to: our ability to market and sell our products including our novel multiplexing technologies and detection platforms; our ability to maintain any technical or product advantages; the success of our Diagnostic Tools and Services business and our intent to build near-term revenue streams from this business; the successful regulatory filing and receipt of regulatory approvals for our later stage quantitative diagnostic kits; adverse changes in general economic conditions; international risk and currency exchange fluctuations; competitor activity; technology changes; regulatory approvals and the impact of healthcare reform legislation; and, SQI's ability to raise additional funds in the future.

Such statements, risks and uncertainties are detailed in the Company's ongoing filings with the securities regulatory authorities, and are available to the public at www.sedar.com. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Investment Summary



Financial growth

- Revenue expected to increase 250% to 4.4 million in 2019
- Product gross margins >65% resulting in strong cash generation with sales growth



Strong customer base

- Customers include established diagnostics and global biopharma customers with strong qualified pipeline
- Existing customer base includes imaware and University Health Network



Fully approved and commercializing

- SQI is continuing to commercialize their proprietary technologies and research and development to fuel their growth in clinical testing
- Maximizing recurring revenue through the sale of consumable testing kits used with SQI testing instruments

What We Do?


SQI analyzes blood samples for multiple indications

SQI Offering vs. Standard ELISA

SQI products save time and reduce costs, with superior technical performance offering 10 unique results per patient sample



Standard ELISA
(semi-manual operation)



sqidlite™
(fully automated operation)

10 biomarker panel
100,000 patient samples

Blood Samples Required	10 blood samples/patient	1 small blood sample/patient
Duplicates	20 if using duplicates	no duplicates needed
# of Kits	20,180 ELISA Kits	1,042 SQI Kits
Days of labour	870 days of labour	34 days of labour on 2 sqidlites
Time per patient	50 minutes/patient	30 seconds/patient



ELISA - Enzyme-Linked Immunosorbent Assay is the commonly used form of blood testing

SQL Revenues




SQL offers a full range of customized solutions to clinical diagnostic testing and testing for new drug development

- SQL offers state-of-the-art customized solutions that can be used in diagnostic testing for existing issues and testing for drug development
- SQL business model is based on driving recurring revenue by selling consumable testing kits used with SQL proprietary testing platforms

Proprietary Instruments	Testing Kits	Services
<ul style="list-style-type: none">• sqidworks™<ul style="list-style-type: none">• Solution for high volume labs• sqidlite™<ul style="list-style-type: none">• Benchtop solution for mid-size facility• sqid-X™<ul style="list-style-type: none">• Budget semi-automated solution	<ul style="list-style-type: none">• Custom diagnostics• Custom pharma• FDA-cleared tests• Off the shelf biomarkers• Drive Recurring Revenue• Portable across instruments• Revenue of up to \$20/sample	<ul style="list-style-type: none">• Rapid kit development• Pharma testing services• CLIA testing services• Co-development for specific indicators with industry thought leaders

SQI Product Portfolio

The SQI product portfolio automates the clinical testing process to increase efficiencies up to 40%

Product	Description	Samples per year	Price
 <p>sqidworks™</p>	<p>Ideal for high-volume labs, sqidworks runs three plates at a time, with just 30 minutes hands-on time.</p>	<p>FULLY AUTOMATED +150k SAMPLES /YR</p>	<p>\$320k</p>
 <p>sqidlite™</p>	<p>A practical benchtop workhorse that allows you to process one plate per run, after only 20 minutes setup.</p>	<p>FULLY AUTOMATED 75k-130k SAMPLES/YR</p>	<p>\$220k</p>
 <p>sqid-X™</p>	<p>Access all the multiplexing power of our Ig_plex technology on a budget, with our semi-automated system.</p>	<p>semi AUTOMATED 100k SAMPLES /YR</p>	<p>\$90k</p>

SQI Existing Customers and Pipeline

SQI shift in focus from research and development to commercialization underway with a strong qualified pipeline

Current Customers	Pipeline
-------------------	----------

- 6 consecutive quarters of growth in kit sales
- Strong existing customer base
- Partnerships with established pharma and diagnostic testing facilities

- Development of new at-home testing kits with existing and new partners
- Partnerships with industry thought leaders to support further research and improvement in diagnostic testing
- Large pharmaceutical companies that want to streamline testing for new drug development



Strategy Overview

SQL offers a unique approach by combining research and development and commercialization aspects to testing

1. Toronto's University Health Network partnership

- SQL entered an agreement to develop a new point-of-care diagnostic device and multiplex testing kit to assess the suitability of organs for transplantation resulting in immediate revenues of \$1.1 million and high potential for recurring revenue upon completion

2. Organic growth

- SQL will focus on growth in existing kits and work with partners to develop new testing kits with a qualified pipeline that can more than double existing revenue
- Additional product development projects exist with current customers (UHN/imaware) that are incrementally much larger than current products being sold

3. CLIA test facility

- SQL is launching a fully integrated the testing service in the US with the establishment of a testing facility adding an incremental service-based revenue stream to kit sales, and increasing cash flow for each kit sold

Strategy Overview – UHN Pilot

The UHN Partnership will allow SQI to develop a solution that has the potential to be licensed internationally

- SQI and UHN are collaborating to develop a novel Lung Transplant test
- SQI will be developing a new point-of-care diagnostic device as well as kits and systems to complement the device
- Dr. Shaf Keshavjee of the University Health Network is an award-winning, world-renowned surgeon who specializes in lung transplants
- The research has the potential to be used not only to test lungs for transplants but also other organs in life-saving transplant operations
- Valued at \$1.1 million in revenue over the next 12 months for services (excluding potential recurring revenue of ~\$10K per patient)




Dr. Shaf Keshavjee

- The George Armstrong Peters Young Investigator Award
- Canada's Top 40 Under 40 Award
- The Colin Woolf Award for Excellence in Continuing Medical Education
- The Lister Prize in Surgery
- Inducted to Order of Canada
- Two Queen's Jubilee medals
- Internationally recognized for Ex Vivo Lung Perfusion System

Strategy Overview – Organic Growth

SQI has 6 consecutive quarters of growth in sales of diagnostic testing kits and pharmaceutical development testing kits

- SQI solutions provide significant opportunities for recurring revenue through the sale of diagnostic and new drug development testing kits
- SQI continues to establish new partnerships to develop new instruments and the accompanying kits that drive recurring revenue
- SQI pipeline includes global pharmaceutical companies and further penetration into the highly fragmented diagnostic testing center industry



Strategy Overview – CLIA Testing Facility

First SQI CLIA testing facility expected to be in production June 2019 to offer full service diagnostic testing to customers

- SQI is in the process of validating and establishing a CLIA-lab
 - CLIA: Clinical Laboratory Improvements Amendment
- Diagnostic testing centers prefer to spend time analyzing results not processing samples
- The new facility will fuel further top line growth through in-house testing of SQI kits
- Expected “in-production” date of Q3 2019, pending regulatory approval
- This one CLIA facility can consolidate nation-wide testing volume from all customers creating significant operating efficiencies


CLIA Testing Facility Location



Financial Forecast

Through recurring revenue and qualified pipeline, SQI is positioned for strong growth in 2019

Recurring Test Kit Revenue Forecast
(C\$ 000s)





- SQI has 3 distinct revenue streams
 - Kit sales (recurring)
 - Instrument/platform sales
 - Service revenue for product development and CLIA testing services



Key Performance Indicators

SQL is focused on increasing sales and optimizing margins through providing superior products and improving customer efficiencies



>65%
Margin on Testing Kits


20%
Revenue growth over
past 6 quarters

\$22 billion
Untapped market size



Future Milestones and Execution

SQI is well positioned to supplement a commercialization aspect to their strong research expertise



Notes

RALI-DX: Rapid Acute Lung Injury Diagnostic test targeted at providing early diagnosis of Acute Respiratory Distress Syndrome
PULS FDA Clearance: SQI has transformed 7 of Predictive Health Diagnostics' 9 biomarkers for the PULS™ Cardiac Test (the "PULS Test") into an SQI-based multiplex test and is expecting FDA approval

Executive Team

SQL leadership team has vast experience ranging from corporate strategy and development to scientific expertise in biotechnology

Andrew Morris
Chief Executive Officer

Experience in corporate finance, corporate development and business strategy to lead the shift from research to commercialization.



Patricia Lie
VP Finance

Over 20 years of financial and strategic management experience and holds CA and CFA designations.



Eric Brouwer
Chief Scientific Officer

Expertise in implementing market-leading technologies in FDA and ISO-regulated environments.




Aye Nyein San
VP Engineering

Over 10 years of experience in the medical device industry, with a breadth of experience and liquid handling systems.




Russ Peloquin
VP Sales and Marketing

Experience with biotechnology companies, leading high-level contract negotiations in the clinical diagnostics arena.



Peter Lea
Founder

Invented and patented the multiplexing microarray technology at the core of SQL Diagnostics.



Board of Directors

SQI Board of Directors own ~68% of the company and are aligned to maximize shareholder value

Clive J. Beddoe

Chair

Affiliations:



Gerald R. Connor

Board Member

Affiliations:



Wilmot L. Matthews

Board Member

Affiliations:



Claude Ricks

Board Member

Affiliations:



Eric Schneider

Board Member

Affiliations:



Eric Zwisler

Board Member

Affiliations:



Andrew Morris

Board Member

Affiliations:



Company Snapshot

SQI Diagnostics Inc. (TSXV:SQD) – Market Information

Ticker:	TSX-V:SQD
Traded on:	OTCQ :SQIDF
Shares Outstanding:	186.6 M
Market Cap:	~\$28 M (May 2019)

SQI Diagnostics Inc. (TSXV:SQD) – Warrant Information

Number of Warrants	Exercise Price	Maturity
5,330,000	\$0.64	July 16, 2020
3,560,000	\$0.59	January 30, 2020 and February 20, 2020
7,631,000	\$0.52	December 15 and 21, 2020
22,970,000	\$0.21	March 10, 2022
463,000	\$0.20	December 20, 2020
54,532,000	\$0.20	December 20, 2022 – August 24, 2023
28,227,000	\$0.11	March 1 and 8, 2024
122,713,000		

SQI Diagnostics Inc. (TSXV:SQD) – Capital Structure


Shareholders	# of shares	%
Insiders	129,113,941	69.2%
Clive Beddoe/Hanover	41,515,238	22.2%
Wilmot Matthews/Marjad	41,500,197	22.2%
Gerald Connor/Cumberland	41,216,455	22.1%
Other Board Members	2,372,792	1.3%
Management	2,509,259	1.3%
Public Float	57,493,301	30.8%
Total Shares Outstanding	186,607,242	100%
Options	8,629,000	
Warrant	122,713,000	

SQI Diagnostics Inc. (TSXV:SQD) – Option Information

Number of Options	Range of Exercise Prices
6,324,000	\$ 0.14 - 0.25
1,972,000	\$ 0.26 – 0.39
333,000	\$ 0.40 – 0.60
8,629,000	



Sqi
DIAGNOSTICS



APPENDIX

BLUE SKY OPPORTUNITY

BLUE SKY OPPORTUNITY						
		<i>Annualized Recurring Revenue Potential</i>				
Patient Samples tested per month		Clinical or Direct to Consumer Kits		CLIA Testing Services	=	TOTAL KIT REVENUE
	10,000 --->	\$ 2,770,000	+	\$ 2,400,000	=	\$ 5,170,000
	30,000 --->	\$ 7,480,000	+	\$ 7,200,000	=	\$ 14,680,000
2024	50,000 --->	\$ 11,220,000	+	\$ 12,000,000	=	\$ 23,220,000


- Positive cash flow driven by high margin kits sales

Focus on Two Major Dx Markets

Dx Target Markets Size Estimates

2017

Global IVD Market	\$ 59 billion
US IVD Market Total (2017)	\$ 23 billion
Addressable Segments Estimate (Autoimmune, Cardiac, Inflammatory, Respiratory, Transplant, Other)	20%
Clinical Dx Reagents (Kits) as % of Total Market	66%



Addressable IVD Market for Kits \$ 3.04 billion

Direct to Consumer Kits \$ 350 million

Total \$ 3.39 billion

North America Biopharma

Biopharma Drug Development Testing	\$ 11 billion
Reagents/Kits as % of Total Market	66%
Key SQI Addressable Segments (biomarkers, cytokines, immunogenicity)	33%



Addressable Biopharma \$ 2.40 billion

PREDICTIVE HEALTH DIAGNOSTICS - CARDIAC PULS TEST = UNMET NEED

- 7 Plex panel for cardiac markers combined with a proprietary algorithm
- Test predicts with 80% confidence likelihood of an adverse cardiac event forward for five years
- Important as it provides forward-looking evidence to guide lifestyle changes or interventional treatment well ahead of an event
- Customer currently running tests at their CLIA lab in California
- SQI projected revenue to be ~\$ 15.00 per test with volumes of 10,000 samples per month exiting Q4 2019

● For more information go to www.pulstest.com











IMAWARE - DIRECT TO CONSUMER

- Direct to consumer strategy, large investment in on-line marketing, sales and fulfillment
- 2 sqidlites validated in Sept18
- SQI's celiac product launch Dec18
- Followed by celiac monitoring subscription launched Jan19
- SQI's rheumatoid arthritis product Jan19
- Follow-on products to be developed for imaware –cardiac health, men's health, other....
- A minimum number of kits to be purchased by imaware to maintain retail market exclusivity
- Celiac Disease affects at least 3 million Americans. It is the most common — and one of the most underdiagnosed -- hereditary autoimmune conditions in the United States today.
- Rheumatoid Arthritis which afflicts 1% of the world's population and where 1.3 million prescriptions will be written this year
- For more information go to imaware.health




Comparable Companies

Comparable figures are Last Quarter 2018 Annualized \$,000s
USD

Company	Market Cap (,000s)	Revenue	Kit Revenue	Service Revenue	Price to sales	Gross Margin (kits)	Gross Margin (Service)	R&D Expense	Operating Profit	Operating Cash Burn	Accumulated Deficit
 PACIFIC BIOSCIENCES™	\$ 1,200,000	\$ 72,640	\$ 60,600	\$ 12,040	17X	19%	10%	\$ 57,424	(98,680)	(109,524)	(951,000)
 Quanterix™	\$ 545,000	\$ 33,496	\$ 20,800	\$ 12,696	16X	43%	46%	\$ 14,820	(29,244)	(76,832)	(167,000)
 FLUIDIGM™	\$ 830,000	116,000	\$ 97,200	\$ 18,800	7X	52%	68%	\$ 29,720	(46,512)	(62,588)	(544,000)
 natera™ Conceive. Deliver. Thrive.	\$ 1,420,000	261,120	\$ 248,000	\$ -	5X	37%	0%	\$ 52,000	(108,664)	(117,992)	(542,688)
 T2 Biosystems™	\$ 115,000	9,864	\$ 4,872	\$ 4,992	12X	neg		\$ 10,900	(43,068)	(51,244)	(302,022)
 myriad® WHEN DECISIONS MATTER	\$ 2,068,000	808,000	\$ 756,000	\$ 53,200	3X	32%	38%	\$ 84,000	4,800	(18,800)	
 GenMark Dx™	\$ 415,000	\$ 62,852	\$ 62,852	\$ -	7X	9%	0	\$ 29,343	(49,547)	(39,947)	(455,000)
Averages	\$ 941,857	\$ 194,853	\$ 178,618	\$ 14,533	9X	32%	27%	\$ 39,744	(52,988)	(68,132)	(493,618)
 sqi DIAGNOSTICS	\$ 21,374	\$ 1,719	\$ 800	1100	12X	>65%	90%	\$ 4,410	(5,952)	(6,605)	(86,000)



SQI
DIAGNOSTICS



CONTACT INFORMATION:

SQI DIAGNOSTICS INC.

36 METEOR DRIVE

TORONTO, CANADA M9W 1A4

IR@SQIDIAGNOSTICS.COM/AMORRIS@SQIDIAGNOSTICS.COM

416-674-9500 /X229